Related Experiment Video

Updated: Jun 24, 2026

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

Iron deficiency in infancy predicts altered serum prolactin response 10 years later

Barbara Felt1, Elias Jimenez, Julia Smith

  • 1Center for Human Growth and Development, Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI 48109-0406, USA. truefelt@umich.edu

Pediatric Research
|September 13, 2006
PubMed

Insights

Childhood iron deficiency (ID) may alter serum prolactin levels long-term. Chronic ID in infancy was linked to an altered prolactin response pattern in adolescence, suggesting lasting effects on CNS regulation.

Area of Science:

  • Neuroendocrinology
  • Pediatric Iron Metabolism

Background:

  • Serum prolactin may indicate central nervous system (CNS) dopaminergic function.
  • Iron deficiency (ID) in rats affects brain dopamine, prompting investigation into infant iron status and serum prolactin.
  • Previous studies linked high serum prolactin to behaviors associated with chronic ID in infants.

Purpose of the Study:

  • To investigate the long-term impact of infant iron status on serum prolactin levels in early adolescence.
  • To determine if early-life iron deficiency influences the neuroendocrine stress response later in life.

Main Methods:

  • Serum prolactin levels were measured in adolescents (11-14 years) who were previously categorized by iron status in infancy (chronic ID vs. good iron).
  • Measurements were taken after a stressor (catheter placement).
  • Serum prolactin patterns were analyzed, controlling for sex, pubertal status, and background factors.

Main Results:

  • Adolescents with a history of chronic ID showed a significantly different serum prolactin response pattern compared to the good iron group.
  • Specifically, serum prolactin levels declined earlier in the chronic ID group.
  • Sex and pubertal maturation influenced baseline prolactin levels, with females and more mature adolescents having higher concentrations.

Conclusions:

  • Chronic iron deficiency in infancy may have lasting effects on the regulation of serum prolactin, observable a decade later.
  • The altered prolactin response pattern suggests a potential long-term impact of early ID on CNS dopaminergic pathways.
  • Further research is warranted to understand the full implications of early ID on neuroendocrine development.

More Related Videos

Concurrent Collection of Fetal Murine Brain and Serum to Assess Effects of Maternal Diet on Nutrition and Neurodevelopment in Neurofibromatosis Type 105:44

Concurrent Collection of Fetal Murine Brain and Serum to Assess Effects of Maternal Diet on Nutrition and Neurodevelopment in Neurofibromatosis Type 1

Published on: May 17, 2024

Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining07:32

Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining

Published on: May 23, 2025

Related Concept Videos

Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...